Dashboard
Manage Tickers

MOLNMOLECULAR PARTNERS AG

Nasdaq molecularpartners.com


$ 4.11 $ 0.33 (8.11 %)    

Monday, 10-Jun-2024 15:27:16 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 464.61 $ 1.82 (0.39 %)
DIA $ 389.34 $ 0.80 (0.21 %)
SPY $ 535.72 $ 1.71 (0.32 %)
TLT $ 90.89 $ -0.61 (-0.67 %)
GLD $ 213.56 $ 1.94 (0.92 %)
$ 4.4
$ 4.11
$ 0.00 x 0
$ 0.00 x 0
$ 4.11 - $ 4.11
$ 3.32 - $ 6.80
260
na
159.96M
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

why-science-applications-international-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Science Applications International Sha...
06/03/2024 17:56:53

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
06/03/2024 12:07:05

why-gamestop-shares-are-trading-higher-here-are-20-stocks-moving-premarket
Why GameStop Shares Are Trading Higher; He...
06/03/2024 09:35:57

reported-saturday-molecular-partners-presented-data-from-completed-phase-1-trial-of-mp0317-monotherapy-in-advanced-solid-tumors-at-asco-2024
Reported Saturday, Molecular Partners Pres...
06/03/2024 09:03:09

Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironment Favor...

molecular-partners-expects-to-be-funded-into-2026-with-cash-and-short-term-deposits-of-chf-1741m-expects-total-operating-expenses-of-chf-70-80-million-for-2024
Molecular Partners Expects To Be Funded In...
05/16/2024 20:16:35

molecular-partners-announces-publication-in-cancer-immunology-research-of-preclinical-data-supporting-mp0533s-proposed-mechanism-of-action
Molecular Partners Announces Publication I...
04/29/2024 15:01:22

Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while s...

molecular-partners-fy-2023-gaap-eps-213-misses-200-estimate-sales-7894m-beat-5333m-estimate
Molecular Partners FY 2023 GAAP EPS $(2.13...
03/14/2024 20:11:22

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(2.13) per share which missed the analyst consensus estimate of ...

earnings-scheduled-for-march-14-2024
Earnings Scheduled For March 14, 2024
03/14/2024 09:52:13

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

molecular-partners-ag-says-class-action-complaint-against-company-has-been-dismissed-in-cos-favor
Molecular Partners AG Says Class Action Co...
03/01/2024 21:23:52

- Reuters

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
01/04/2024 13:05:58

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
01/03/2024 21:31:05

molecular-partners-presented-initial-data-from-first-four-dosing-cohorts-of-ongoing-phase-12a-trial-of-mp0533-for-patients-with-relapsedrefractory-aml-and-amlmds-at-2023-ash--meeting
Molecular Partners Presented Initial Data ...
12/10/2023 17:51:47

Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protei...

jp-morgan-maintains-neutral-on-molecular-partners-lowers-price-target-to-45
JP Morgan Maintains Neutral on Molecular P...
12/05/2023 15:48:29

JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lowers the price target from ...

molecular-partners-to-present-on-darpin-oncology-innovations-at-protein--antibody-engineering-summit-europe
Molecular Partners To Present On DARPin On...
11/14/2023 07:06:38

molecular-partners-presents-updated-data-from-ongoing-phase-1-trial-of-mp0317-monotherapy-in-patients-with-advanced-solid-tumors-at-the-2023-sitc-annual-meeting
Molecular Partners Presents Updated Data F...
11/03/2023 16:09:53

MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironm...

molecular-partners-to-present-initial-data-from-ongoing-phase-12a-trial-of-mp0533-for-patients-with-relapsedrefractory-aml-and-amlmds-at-the-65th-ash-annual-meeting-and-exposition
Molecular Partners To Present Initial Data...
11/02/2023 07:00:46

As of data cut-off (20 July 2023) of the abstract published today, five patients across three dosing regimens had been treated....

molecular-partners-announces-interim-management-statement-for-q3-2023
Molecular Partners Announces Interim Manag...
10/26/2023 20:04:47

MP0317 Phase 1 dose escalation recruitment completed in patients with advanced solid tumors; updated clinical results to be pre...

molecular-partners-to-present-new-data-on-its-radio-darpin-therapy-rdt-platform-at-the-eanm-2023-annual-meeting
Molecular Partners To Present New Data On ...
09/13/2023 06:44:45

stocks-that-hit-52-week-lows-on-thursday
Stocks That Hit 52-Week Lows On Thursday
09/07/2023 17:55:53

  On Thursday, 283 companies set new 52-week lows.

correction-molecular-partners-h1-eps-105-down-from-486-yoy-sales-385m-down-from-19555m-yoy
CORRECTION: Molecular Partners H1 EPS $(1....
08/24/2023 21:11:07

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(1.05) per share. This is a 121.6 percent decrease over earnings...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)